Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Short Interest Up 169.7% in March

Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 8,900 shares, a growth of 169.7% from the March 15th total of 3,300 shares. Based on an average daily volume of 203,300 shares, the short-interest ratio is presently 0.0 days.

Tevogen Bio Stock Up 3.2 %

Shares of TVGNW stock opened at $0.04 on Tuesday. The firm’s 50-day moving average is $0.06 and its two-hundred day moving average is $0.06. Tevogen Bio has a 12 month low of $0.01 and a 12 month high of $0.15.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.